Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1993 Aug;93(2):218–222. doi: 10.1111/j.1365-2249.1993.tb07969.x

Early induction of IL-1 receptor antagonist (IL-1Ra) in infants and children undergoing surgery.

E M O Nualláin 1, P Puri 1, D J Reen 1
PMCID: PMC1554828  PMID: 8348747

Abstract

The cytokine response to injury or trauma is of interest in terms of both its mediation of the acute phase response and its possible relation to the immunological depression observed after major surgery. In this study, the production of cytokines IL-1 beta, tumour necrosis factor-alpha (TNF-alpha), IL-6 and the naturally occurring inhibitor of IL-1, IL-1Ra, have been investigated in infants and children undergoing Swenson's pull-through operation for Hirschsprung's disease. Samples of peripheral blood were taken before, during and after surgery for the measurement of cytokines. IL-1Ra levels increased significantly (P < 0.01) at 2 h after commencement of surgery, with maximal levels for individual patients being attained between 3 h and 5 h (range 7.6-67.9 ng/ml). The mean level of IL-1Ra was maximal (26.2 ng/ml) at 5 h and returned to baseline levels between 24 h and 72 h. There were no changes observed in the circulating levels of IL-1 beta in nine out of 11 patients following commencement of surgery. TNF-alpha levels did not increase in any of the patients studied. IL-6 levels increased significantly (P < 0.02) 3 h after commencement of surgery, reaching maximum concentrations at 24 h (range 20-670 pg/ml), with levels falling between 48 h and 72 h. This study demonstrates, in vivo, the independent induction of IL-1Ra without a concomitant increase of IL-1 beta levels after major surgery. It also shows that IL-1Ra is the earliest cytokine produced in response to surgical stress.

Full text

PDF
218

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alexander H. R., Doherty G. M., Venzon D. J., Merino M. J., Fraker D. L., Norton J. A. Recombinant interleukin-1 receptor antagonist (IL-1ra): effective therapy against gram-negative sepsis in rats. Surgery. 1992 Aug;112(2):188–194. [PubMed] [Google Scholar]
  2. Baigrie R. J., Lamont P. M., Dallman M., Morris P. J. The release of interleukin-1 beta (IL-1) precedes that of interleukin 6 (IL-6) in patients undergoing major surgery. Lymphokine Cytokine Res. 1991 Aug;10(4):253–256. [PubMed] [Google Scholar]
  3. Buckingham J. C. Hypothalamo-pituitary responses to trauma. Br Med Bull. 1985 Jul;41(3):203–211. doi: 10.1093/oxfordjournals.bmb.a072052. [DOI] [PubMed] [Google Scholar]
  4. Cominelli F., Nast C. C., Duchini A., Lee M. Recombinant interleukin-1 receptor antagonist blocks the proinflammatory activity of endogenous interleukin-1 in rabbit immune colitis. Gastroenterology. 1992 Jul;103(1):65–71. doi: 10.1016/0016-5085(92)91096-m. [DOI] [PubMed] [Google Scholar]
  5. Conti P., Panara M. R., Porrini A. M., Gambi D., Barbacane R. C., Reale M., Bongrazio M., Dempsey R. A. Inhibition of interleukin-1 (alpha and beta), interleukin-2 secretion and surface expression of interleukin-2 receptor (IL-2R) by a novel cytokine interleukin-1 receptor antagonist (IL-1ra). Scand J Immunol. 1992 Jul;36(1):27–33. doi: 10.1111/j.1365-3083.1992.tb02937.x. [DOI] [PubMed] [Google Scholar]
  6. Dayer J. M. Chronic inflammatory joint diseases: natural inhibitors of interleukin 1 and tumor necrosis factor alpha. J Rheumatol Suppl. 1991 Feb;27:71–75. [PubMed] [Google Scholar]
  7. Di Padova F., Pozzi C., Tondre M. J., Tritapepe R. Selective and early increase of IL-1 inhibitors, IL-6 and cortisol after elective surgery. Clin Exp Immunol. 1991 Jul;85(1):137–142. doi: 10.1111/j.1365-2249.1991.tb05694.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Dinarello C. A. Interleukin-1 and interleukin-1 antagonism. Blood. 1991 Apr 15;77(8):1627–1652. [PubMed] [Google Scholar]
  9. Dinarello C. A. Role of interleukin-1 in infectious diseases. Immunol Rev. 1992 Jun;127:119–146. doi: 10.1111/j.1600-065x.1992.tb01411.x. [DOI] [PubMed] [Google Scholar]
  10. Dripps D. J., Brandhuber B. J., Thompson R. C., Eisenberg S. P. Interleukin-1 (IL-1) receptor antagonist binds to the 80-kDa IL-1 receptor but does not initiate IL-1 signal transduction. J Biol Chem. 1991 Jun 5;266(16):10331–10336. [PubMed] [Google Scholar]
  11. Eisenberg S. P., Brewer M. T., Verderber E., Heimdal P., Brandhuber B. J., Thompson R. C. Interleukin 1 receptor antagonist is a member of the interleukin 1 gene family: evolution of a cytokine control mechanism. Proc Natl Acad Sci U S A. 1991 Jun 15;88(12):5232–5236. doi: 10.1073/pnas.88.12.5232. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Faherty D. A., Claudy V., Plocinski J. M., Kaffka K., Kilian P., Thompson R. C., Benjamin W. R. Failure of IL-1 receptor antagonist and monoclonal anti-IL-1 receptor antibody to inhibit antigen-specific immune responses in vivo. J Immunol. 1992 Feb 1;148(3):766–771. [PubMed] [Google Scholar]
  13. Fischer E., Marano M. A., Van Zee K. J., Rock C. S., Hawes A. S., Thompson W. A., DeForge L., Kenney J. S., Remick D. G., Bloedow D. C. Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia. J Clin Invest. 1992 May;89(5):1551–1557. doi: 10.1172/JCI115748. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Fischer E., Van Zee K. J., Marano M. A., Rock C. S., Kenney J. S., Poutsiaka D. D., Dinarello C. A., Lowry S. F., Moldawer L. L. Interleukin-1 receptor antagonist circulates in experimental inflammation and in human disease. Blood. 1992 May 1;79(9):2196–2200. [PubMed] [Google Scholar]
  15. Fong Y., Moldawer L. L., Shires G. T., Lowry S. F. The biologic characteristics of cytokines and their implication in surgical injury. Surg Gynecol Obstet. 1990 Apr;170(4):363–378. [PubMed] [Google Scholar]
  16. Girardin E., Grau G. E., Dayer J. M., Roux-Lombard P., Lambert P. H. Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. N Engl J Med. 1988 Aug 18;319(7):397–400. doi: 10.1056/NEJM198808183190703. [DOI] [PubMed] [Google Scholar]
  17. Granowitz E. V., Clark B. D., Mancilla J., Dinarello C. A. Interleukin-1 receptor antagonist competitively inhibits the binding of interleukin-1 to the type II interleukin-1 receptor. J Biol Chem. 1991 Aug 5;266(22):14147–14150. [PubMed] [Google Scholar]
  18. Granowitz E. V., Porat R., Mier J. W., Pribble J. P., Stiles D. M., Bloedow D. C., Catalano M. A., Wolff S. M., Dinarello C. A. Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans. Cytokine. 1992 Sep;4(5):353–360. doi: 10.1016/1043-4666(92)90078-6. [DOI] [PubMed] [Google Scholar]
  19. Granowitz E. V., Santos A. A., Poutsiaka D. D., Cannon J. G., Wilmore D. W., Wolff S. M., Dinarello C. A. Production of interleukin-1-receptor antagonist during experimental endotoxaemia. Lancet. 1991 Dec 7;338(8780):1423–1424. doi: 10.1016/0140-6736(91)92725-h. [DOI] [PubMed] [Google Scholar]
  20. Green D. R., Faist E. Trauma and the immune response. Immunol Today. 1988 Sep;9(9):253–255. doi: 10.1016/0167-5699(88)91300-X. [DOI] [PubMed] [Google Scholar]
  21. Gruss H. J., Dölken G., Brach M. A., Mertelsmann R., Herrmann F. High concentrations of the interleukin-1 receptor antagonist in serum of patients with Hodgkin's disease. Lancet. 1992 Oct 17;340(8825):968–968. doi: 10.1016/0140-6736(92)92849-b. [DOI] [PubMed] [Google Scholar]
  22. Henderson B., Thompson R. C., Hardingham T., Lewthwaite J. Inhibition of interleukin-1-induced synovitis and articular cartilage proteoglycan loss in the rabbit knee by recombinant human interleukin-1 receptor antagonist. Cytokine. 1991 May;3(3):246–249. doi: 10.1016/1043-4666(91)90023-7. [DOI] [PubMed] [Google Scholar]
  23. Kelley C. J., Ingoldby C. J., Blenkharn J. I., Wood C. B. Colonoscopy related endotoxemia. Surg Gynecol Obstet. 1985 Oct;161(4):332–334. [PubMed] [Google Scholar]
  24. Larrick J. W. Native interleukin 1 inhibitors. Immunol Today. 1989 Feb;10(2):61–66. doi: 10.1016/0167-5699(89)90308-3. [DOI] [PubMed] [Google Scholar]
  25. Malyak M., Joslin F. G., Verderber E. L., Eisenberg S. P., Arend W. P. IL-1ra ELISA: reduction and alkylation of synovial fluid eliminates interference by IgM rheumatoid factors. J Immunol Methods. 1991 Jul 5;140(2):281–288. doi: 10.1016/0022-1759(91)90381-o. [DOI] [PubMed] [Google Scholar]
  26. McIntyre K. W., Stepan G. J., Kolinsky K. D., Benjamin W. R., Plocinski J. M., Kaffka K. L., Campen C. A., Chizzonite R. A., Kilian P. L. Inhibition of interleukin 1 (IL-1) binding and bioactivity in vitro and modulation of acute inflammation in vivo by IL-1 receptor antagonist and anti-IL-1 receptor monoclonal antibody. J Exp Med. 1991 Apr 1;173(4):931–939. doi: 10.1084/jem.173.4.931. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Michie H. R., Manogue K. R., Spriggs D. R., Revhaug A., O'Dwyer S., Dinarello C. A., Cerami A., Wolff S. M., Wilmore D. W. Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med. 1988 Jun 9;318(23):1481–1486. doi: 10.1056/NEJM198806093182301. [DOI] [PubMed] [Google Scholar]
  28. Murata A., Ogawa M., Yasuda T., Nishijima J., Oka Y., Ohmachi Y., Hiraoka N., Niinobu T., Uda K., Mori T. Serum interleukin 6, C-reactive protein and pancreatic secretory trypsin inhibitor (PSTI) as acute phase reactants after major thoraco-abdominal surgery. Immunol Invest. 1990 Jun;19(3):271–278. doi: 10.3109/08820139009041842. [DOI] [PubMed] [Google Scholar]
  29. Nicod L. P., el Habre F., Dayer J. M. Natural and recombinant interleukin 1 receptor antagonist does not inhibit human T-cell proliferation induced by mitogens, soluble antigens or allogeneic determinants. Cytokine. 1992 Jan;4(1):29–35. doi: 10.1016/1043-4666(92)90033-n. [DOI] [PubMed] [Google Scholar]
  30. Nishimoto N., Yoshizaki K., Tagoh H., Monden M., Kishimoto S., Hirano T., Kishimoto T. Elevation of serum interleukin 6 prior to acute phase proteins on the inflammation by surgical operation. Clin Immunol Immunopathol. 1989 Mar;50(3):399–401. doi: 10.1016/0090-1229(89)90147-5. [DOI] [PubMed] [Google Scholar]
  31. Okusawa S., Gelfand J. A., Ikejima T., Connolly R. J., Dinarello C. A. Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J Clin Invest. 1988 Apr;81(4):1162–1172. doi: 10.1172/JCI113431. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Seckinger P., Isaaz S., Dayer J. M. Purification and biologic characterization of a specific tumor necrosis factor alpha inhibitor. J Biol Chem. 1989 Jul 15;264(20):11966–11973. [PubMed] [Google Scholar]
  33. Shenkin A., Fraser W. D., Series J., Winstanley F. P., McCartney A. C., Burns H. J., Van Damme J. The serum interleukin 6 response to elective surgery. Lymphokine Res. 1989 Summer;8(2):123–127. [PubMed] [Google Scholar]
  34. Spinas G. A., Keller U., Brockhaus M. Release of soluble receptors for tumor necrosis factor (TNF) in relation to circulating TNF during experimental endotoxinemia. J Clin Invest. 1992 Aug;90(2):533–536. doi: 10.1172/JCI115891. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Sullivan J. S., Kilpatrick L., Costarino A. T., Jr, Lee S. C., Harris M. C. Correlation of plasma cytokine elevations with mortality rate in children with sepsis. J Pediatr. 1992 Apr;120(4 Pt 1):510–515. doi: 10.1016/s0022-3476(05)82476-x. [DOI] [PubMed] [Google Scholar]
  36. Sweed Y., Puri P., Reen D. J. Early induction of IL-6 in infants undergoing major abdominal surgery. J Pediatr Surg. 1992 Aug;27(8):1033–1037. doi: 10.1016/0022-3468(92)90553-j. [DOI] [PubMed] [Google Scholar]
  37. Waage A., Espevik T. Interleukin 1 potentiates the lethal effect of tumor necrosis factor alpha/cachectin in mice. J Exp Med. 1988 Jun 1;167(6):1987–1992. doi: 10.1084/jem.167.6.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Weissman C. The metabolic response to stress: an overview and update. Anesthesiology. 1990 Aug;73(2):308–327. doi: 10.1097/00000542-199008000-00020. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES